生物类似药治疗风湿病的共识建议
一个来自十国的风湿病学、皮肤科、胃肠病学专家、药理学家、患者及监管者组成的工作组,通过德尔菲法和系统文献综述,制定了关于生物类似药评估与使用的5项总体原则和8项共识建议,涵盖临床试验、免疫原性、适应症外推、转换及成本等。
要点
- 共识涵盖生物类似药的临床试验、免疫原性、适应症外推、转换和成本等关键议题。
- 共形成5项总体原则和8项共识建议,证据等级和推荐强度因现有证据而异。
- 系统检索识别490篇参考文献,最终纳入29篇全文和20篇会议摘要。
核心结论
- 基于研究证据和专家意见,制定了关于生物类似药评估与使用的5项总体原则和8项共识建议。
主要发现
- 系统检索共识别490篇参考文献,其中29篇全文纳入系统综述,另从ACR和EULAR会议摘要数据库检索到20篇摘要。
- 最终形成5项总体原则和8项共识建议,涉及临床试验、免疫原性、适应症外推、生物原研药与生物类似药之间及生物类似药之间的转换、成本等考虑。
关键数值与推荐
- 每项共识建议的证据等级和推荐强度根据现有已发表证据确定,且各不相同。
临床怎么用
- 共识建议可用于指导风湿病临床实践中生物类似药的评估、使用、转换及成本考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and pharmacologists, patients and a regulator from ten countries. Four key topics regarding biosimilars were identified through a process of discussion and consensus. Using a Delphi process, specific questions were then formulated to guide a systematic literature review. Relevant English-language publications through November 2016 were searched systematically for each topic using Medline; selected papers and pertinent reviews were examined for additional relevant references; and abstracts presented at the 2015 and 2016 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) annual scientific meetings were searched for those about biosimilars. The experts used evidence obtained from these studies to develop a set of overarching principles and consensus recommendations. The level of evidence and grade of recommendation were determined for each. By the search strategy, 490 references were identified. Of these, 29 full-text papers were included in the systematic review. Additionally, 20 abstracts were retrieved from the ACR and EULAR conference abstract databases. Five overarching principles and eight consensus recommendations were generated, encompassing considerations regarding clinical trials, immunogenicity, extrapolation of indications, switching between bio-originators and biosimilars and among biosimilars, and cost. The level of evidence and grade of recommendation for each varied according to available published evidence. Five overarching principles and eight consensus recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases were developed using research-based evidence and expert opinion.
引用
- Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2017. PMID: 28866648. doi:10.1136/annrheumdis-2017-211937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。